Shots:
The company has developed Versavo as a biosimilar of Avastin, approved for the treatment of various cancer indications incl. metastatic colorectal cancer, advanced non-squamous NSCLC, recurrent glioblastoma, mRCC, advanced cervical cancer, ovarian cancer & metastatic breast cancer
Based on the clinical evaluation, Versavo is expected to be approved and launched across the UK as…
Shots:
Know Your Investor is an earnest effort from PharmaShots to acquaint our readers with leading Investors and venture capital firms in the healthcare industry
Founded in 1969, F-Prime Capital Partners is a subsidiary of Fidelity Investments and primarily invests in healthcare and technology
A total of 40 investments were closed by F-Prime in 2023,…
Spotlight Interview: David A. Dodd, CEO at GeoVax Labs, in an Engaging Conversation with PharmaShots
PharmaShots’ Spotlight offers a unique platform for biopharma, life sciences, and healthcare companies, allowing them to connect with their target audiences and like-minded people.
This week at the Spotlight, we had a riveting discussion with David A. Dodd, Chairman, President & CEO, at GeoVax Labs.
David eloquently highlighted GeoVax’s extraordinary journey over the years from…
Shots:
Betty Woo, VP of Cell, Gene, and Advanced Therapies, Thermo Fisher Scientific discusses the evolution of ThermoFisher’s strategic collaboration with ArsenalBio
Betty highlights the development of programmable autologous T cells for the treatment of cancer and the cell therapy collaboration program
Betty believes that through innovation and partnership, they can tap into the full…
Shots:
Moitreyee Chatterjee-Kishore, HOD, Immuno-Oncology & Cancer Cell Therapy at Astellas shares insights from the P-III trials (SPOTLIGHT & GLOW)
In SPOTLIGHT and GLOW, zolbetuximab and chemotherapy demonstrated improved PFS and OS vs placebo plus chemotherapy, yielding positive outcomes for patients with advanced gastric or GEJ cancer.
Moitreyee highlights the ongoing clinical trials for the…
Shots:
PharmaShots' designation report provides a concise overview of several drugs and their designations by the US FDA, the EU, and China. This month’s report includes 10 biological drugs, 15 small molecules, 5 cell and gene therapies, 4 devices, 1 vaccine and 1 microbiota
MicuRx’ Contezolid and Contezolid acefosamil, focused on the treatment of Diabetic…
Shots:
Monoclonal antibodies are transforming therapeutics through their highly efficient targeting mechanisms. There is a wide range of uses for monoclonal antibodies, including diagnosis, therapy, and research
In 2021, the monoclonal antibody therapy market size was valued at $178.5B and is envisioned to reach $451.89B by 2028, displaying a CAGR of 14.1%. Humira was the…
Shots:
To keep our readers acquainted with several disease conditions, ongoing trials, and available treatment options, PharmaShots brings every month a detailed take on a particular disease after thorough research
Continuing the series for the disease of the month, PharmaShots brings a condensed report on Mesothelioma, a type of cancer that affects the lining of…
Shots:
With more than 50% of ongoing clinical trials worldwide in oncology domains, cancer remains one of the leading causes of death worldwide. Oncology companies are steadfastly looking for innovative therapies to cure both hematologic and solid tumor cancer
The global oncology drug market size in 2022 was valued at $185B and is forecasted to…
Are you ready to be part of a global movement to advance cancer research and treatment? This is your chance to connect with leading experts, healthcare professionals, and researchers from around the world.
Conference Series is delighted to welcome you to attend the 23rd World Congress on Cancer and Diagnostics scheduled in Toronto, Canada on…

